Updated:
Elan SBI Capital Partners
Elan SBI Capital Partners was established as a cross-border venture between Elan BioInvest and SBI Holdings, linking US and Asian capital with European...
Elan SBI Capital Partners
Elan SBI Capital Partners was established as a cross-border venture between Elan BioInvest and SBI Holdings, linking US and Asian capital with European and North American life sciences opportunities. The firm is structured as an asset manager rather than a family office, but its roots trace to the capital and networks of its founding partners. The firm's geographic spread—spanning Menlo Park, Cambridge, Baltimore, Basel, and Budapest—reflects a strategy of embedding in key biotech hubs. The firm invests across the life sciences value chain, from early-stage venture through growth equity to buyout-stage opportunities. Asset classes include venture capital, growth equity, and private equity, with a focus on therapeutics, diagnostics, medical devices, and digital health. Notable portfolio positions have included investments in gene therapy platforms, oncology drug developers, and AI-driven diagnostics companies (per public record). The firm’s geographic footprint covers North America, Europe, and Asia, with deal sourcing leveraging relationships from its dual-parent heritage. The firm's total assets under management and number of professionals are not publicly disclosed. Its partnership structure with SBI Holdings suggests access to substantial Asian institutional and high-net-worth capital, though exact deployment figures are unavailable. No philanthropic vehicles or operating companies are publicly associated with the firm. A structural differentiator is the firm's explicit joint-venture model, which blends the scientific and operational expertise of Elan BioInvest with the financial infrastructure of SBI Holdings. This arrangement gives Elan SBI Capital Partners a dual-lens approach—scientific rigor from the Elan side and cross-border capital deployment capability from SBI. The firm operates more like a specialized life sciences asset manager than a traditional family office, with a mandate that covers direct investments and co-investments alongside other institutional partners.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Menlo Park
Corporate office
Menlo Park, CA, United States
Additional offices
Cambridge, MA, United States · Baltimore, MD, United States · Basel, Switzerland · Budapest, Hungary
Sector focus
Frequently asked questions
Who manages investment decisions at Elan SBI Capital Partners?
The specific investment team composition is not publicly disclosed. The firm is led by representatives from both Elan BioInvest and SBI Holdings, with investment decisions likely made by a partnership committee drawing on scientific and financial expertise from both parent entities (per public record).
What investment stages does Elan SBI Capital Partners target?
The firm targets the full life sciences capital stack, including venture capital for early-stage companies, growth equity for later-stage clinical and commercial-stage businesses, and private equity for buyout and structured transactions. This multi-stage approach allows the firm to follow portfolio companies as they mature (per public record).
Is Elan SBI Capital Partners structured as a single family office or an institutional fund manager?
The firm is structured as an asset manager rather than a single family office. It operates as a joint venture between Elan BioInvest (a life sciences investment firm) and SBI Holdings (a Japanese financial conglomerate). Its investment model uses pooled capital from institutional and high-net-worth sources, characteristic of a private equity or venture capital firm.
Which geographies does Elan SBI Capital Partners focus on?
The firm maintains offices in Menlo Park (California), Cambridge (Massachusetts), Baltimore (Maryland), Basel (Switzerland), and Budapest (Hungary). This network covers key life sciences clusters in North America and Europe, with additional access to Asian capital through its SBI Holdings partnership (per public record).
What sectors does Elan SBI Capital Partners explicitly avoid?
The firm's public focus is exclusively on healthcare and life sciences—therapeutics, diagnostics, medical technology, and digital health. There is no indication it invests in other sectors such as technology (outside of healthcare-related applications), energy, or real estate.
How does Elan SBI Capital Partners source deal flow?
Deal sourcing is driven by the firm's dual-parent network: scientific deal flow from Elan BioInvest's relationships with academic medical centers and biotech entrepreneurs, and cross-border capital access from SBI Holdings' Asian institutional network. The firm's geographic office footprint in key biotech clusters also supports proprietary sourcing (per public record).
What is the relationship between Elan SBI Capital Partners and SBI Holdings?
Elan SBI Capital Partners is a joint venture between Elan BioInvest and SBI Holdings. SBI Holdings is a Japanese financial conglomerate with interests in asset management, securities, and banking. This partnership provides the firm with access to Asian capital markets and institutional investors, while Elan BioInvest contributes life sciences investment expertise (per public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: